Imagin Medical – The Next Generation Ultrasensitive Imaging Solutions for Early Detection and Treatment of Cancer
Imagin Medical Inc. is a medical imaging company positioned to radically improve the way physicians detect cancer through the use of endoscopes. The Company is developing the i/Blue Imaging System which they believe will help reduce the recurrence of bladder cancer. This technology will increase urologists’ ability to remove all cancerous cells through an endoscope (cystoscope) by dramatically improving the ability to visualize suspicious masses. Imagin’s system’s unique combination of optical/laser technologies projects white light and near-infrared fluorescence through the scope to increase the imaging sensitivity, greatly reduce the dosage of chemical agents and blend the images so that only one monitor is required during surgery. The i/Blue Imaging System can be seamlessly adapted to most endoscope on the market today.
The company’s products are based on the invention of Dr. Stavros Demos from the Lawrence Livermore National Laboratory (LLNL). Dr. Stavros worked in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer, for more than five years to prove feasibility. IME has entered into a partnership with the LLNL and UC Davis to complete additional clinical evaluations that will support their FDA submission.
Imagin Medical is the developer of the ultrasensitive i/Blue Imaging System that will establish a new standard of care for urologists in detecting cancers and visualizing the surgical field during minimally invasive surgeries. The Company’s initial focus is bladder cancer.
Vancouver, B.C. and Boston, MA, March 2, 2017 – Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (Frankfurt/Stuttgart Stock Exchanges: DPD2) (the “Company”) announced today that the Company and Optel, Inc., its product design partner, have achieved the first steps of their plan for the manufacture and commercialization of the i/Blue™ Imaging System. The Company is working against the key milestones outlined below.
Proof of Concept: Underway - Overall objective is to reduce the size of the current prototype by 70% and create it as a mobile product that can be moved easily between different operating rooms. The platform will include four primary modules: illumination, imaging, image processing, and the power supply. Each module is currently being prototyped to verify that performance meets and/or exceeds specifications. The Company expects the modular platform to be the basis of its future systems.
Design and Construction of Pilot Production Device: 3Q 2017 – The device enclosure will house the four basic modules and be compatible with either cart or rack mounting and a touchscreen display located on its exterior to serve as the graphical user interface.
Verification and Validation Testing: 4Q 2017 - All verification and testing will be conducted in accordance with the requirements of the FDA’s Good Manufacturing Practices (GMP), the European medical device standard ISO 13485 and generally in accordance with other international medical device compliance requirements.
“Optel’s experience and success in the optical medical device field, combined with the capabilities of our development team, gives me confidence that we will achieve our goals on schedule,” commented Jim Hutchens, Imagin’s President and CEO.
About Imagin Medical
Imagin Medical is developing imaging solutions for the early detection of cancer through the use of endoscopes. The Company believes it will radically improve the way physicians detect cancer. Imagin’s initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. Developed at the Lawrence Livermore National Laboratory, this advanced, ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com.
ON BEHALF OF THE BOARD:
President & CEO
For further information, contact:
Bill Galine, Investor Relations
Telephone: (775) 737-3292